CAN-105

N/A

Report date: 2024/11/08 11:24:39

Base Information

Drug NameCAN-105
Drug Alias NameCAN-105
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Factor IXaAnti-Factor X
TargetsCoagulation factor IXCoagulation factor X
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWuxi Biologics Co LtdBeihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCanbridge Life Sciences LtdWuxi Apptec Co LtdBeihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A